Iwicki Mark T 4

What Happened Mark T. Iwicki, a director of Q32 Bio, was granted an award on June 12, 2026 covering 9,810 shares. The grant is reported as a derivative award (code A) with an acquisition price of $0.00, so no cash was exchanged at grant. The filing was made on June 16, 2026.

Key Details

• Transaction date: 2026-06-12 (reported on Form 4 filed 2026-06-16).
• Transaction type/code: Grant/Award (A), derivative security (option-like award), price: $0.00; aggregate value at grant reported as $0.
• Vesting/exercisability: Per footnote, the shares underlying this option vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continued service.
• Shares owned after transaction: Not disclosed in the provided summary (see full Form 4 for total beneficial ownership).
• Timeliness: Form 4 was filed within the usual 2-business-day window (filed 2026-06-16 for a 2026-06-12 transaction).

Context This is a standard director compensation award (a time‑based derivative grant) rather than a cash purchase or sale. The award does not represent exercised options or an immediate sale of shares; it vests in the future subject to continued service. Such grants are common for board members and are generally part of routine compensation.